Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrimination of beef meat according to the level of farming intensification through visible and near infrared spectroscopy data and chemometrics.

Meat science·2026
Same author

Nationwide Analysis of Maternal Mortality Due to Venous Thromboembolism.

Obstetrics and gynecology·2026
Same author

Gynaecological surgery, Assisted Reproductive Technology (ART), Obstetrics, and Interventional Gynaecological and Obstetrical Radiology.

Anaesthesia, critical care & pain medicine·2026
Same author

Rationalizing thrombophilia screening in children: Insights from a 2019 retrospective study at a tertiary care hospital.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same author

[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].

Gynecologie, obstetrique, fertilite & senologie·2025
Same author

Perioperative hemodynamic optimization - Paediatrics.

Anaesthesia, critical care & pain medicine·2025

Related Experiment Video

Updated: Jun 13, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

Which model for propofol TCI in children.

Isabelle Constant1, Agnes Rigouzzo

  • 1Department of Anesthesiology, Armand Trousseau Hospital, Paris, France. isabelle.constant@trs.aphp.fr

Paediatric Anaesthesia
|May 18, 2010
PubMed
Summary

Total intravenous anesthesia (TIVA) using propofol is a viable option for pediatric anesthesia. Developing accurate pharmacokinetic and pharmacodynamic (PKPD) models tailored for children, incorporating factors like age and size, is crucial for safe and effective TIVA.

More Related Videos

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach
06:38

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach

Published on: June 11, 2017

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Related Experiment Videos

Last Updated: Jun 13, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach
06:38

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity (AIDN): A Translational Neuroscience Approach

Published on: June 11, 2017

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Area of Science:

  • Anesthesiology
  • Pharmacokinetics
  • Pharmacodynamics

Background:

  • Total intravenous anesthesia (TIVA) with propofol offers advantages for pediatric anesthesia.
  • Existing pharmacokinetic (PK) models for pediatric TIVA often lack precision due to limited covariates and high variability.
  • Pharmacodynamic (PD) parameters and integrated PKPD models for pediatric propofol anesthesia are not yet established.

Purpose of the Study:

  • To address the need for validated pharmacokinetic and pharmacodynamic (PKPD) models for propofol in pediatric anesthesia.
  • To explore the adaptation of adult models, such as the Schnider model, for pediatric use.
  • To investigate the importance of physiological covariates in pediatric PKPD modeling.

Main Methods:

  • Review of existing 3-compartment PK models for propofol in children.
  • Discussion of the limitations of weight-only covariates in pediatric PK models.
  • Consideration of adapting adult PKPD models (e.g., Schnider) with multiple covariates for children over 5 years.
  • Emphasis on incorporating physiological factors like age and size for improved metabolic process description.

Main Results:

  • Current pediatric PK models for propofol have limitations, including large distribution volumes and significant interindividual variability.
  • The Schnider model, with its inclusion of multiple covariates, shows potential for improved accuracy in describing propofol PKPD in older children.
  • Physiological covariates are essential for accurately modeling metabolic processes during pediatric growth and maturation.

Conclusions:

  • Pediatric TIVA with propofol requires tailored PKPD models that account for growth and maturation.
  • Adapting adult models like Schnider's may offer a more robust approach for children over 5 years.
  • Utilizing pharmacodynamic feedback, such as the bispectral index, can help manage interindividual variability in pediatric propofol anesthesia.